Kripa Rajak
Research Subjects
Kripa Rajak has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Abhigan Babu Shrestha
Patan Academy of Health Sciences Hospital, Lalitpur, Nepal
2 shared publications - Mohamed Chadi Alraies
Detroit Medical Center Detroit Michigan USA
2 shared publications - Mohammad Hamza
Department of Internal Medicine, Albany Medical Center, Albany, NY 12208, USA
2 shared publications - Mustafa Turkmani
Faculty of Medicine Michigan State University East Lansing Michigan USA
2 shared publications - Prakash Upreti
Sands Constellation Heart Institute, Rochester Regional Health, Rochester, NY, USA
2 shared publications - Sidra Naz
The University of Texas, MD Anderson Cancer Center, Texas
2 shared publications
Latest Publications
- 9 October 2025
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
- Vol. 25 (1) , e0406
Medical Management Versus PCI in Patients with Stable Angina: An Updated Systematic Review and Meta-analysis
Background: Despite the clinical guidelines favoring medical therapy for stable angina, the optimal management of these patients remains unclear. Here, we compare medical management (MM) versus percutaneous coronary intervention (PCI) in patients with stable angina. Methods: An extensive literature search was conducted using PubMed and Embase to identify randomized controlled trials of interest. Data were extracted and analyzed using a random-effects model to calculate pooled odds ratios (OR). Results: Our meta-analysis of 28 randomized controlled trials included 9346 PCI patients and 9503 medically managed patients. The mean age was 62.5 ± 7.6 years in the PCI group and 62.8 ± 7.4 years in the other group. Men comprised 68% and 70% of the PCI and MM groups, respectively. Over a mean follow-up of 2.64 years, PCI was associated with a significantly lower incidence of myocardial infarction compared with MM (OR, 0.84; 95% CI, 0.74–0.96; P = 0.01). Although PCI showed trends toward lower odds of unplanned revascularizations and major adverse cardiovascular (CV) events, these differences were not statistically significant. There were no differences in outcomes of freedom from angina, unstable angina, nonfatal myocardial infarction, stroke, all-cause mortality, or CV death. Conclusion: Advances in CV imaging and catheterization techniques have improved risk stratification and outcomes of PCI in stable angina. Further research is needed to identify clinical subgroups that benefit most from each treatment modality.
- 9 October 2025
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
- Vol. 25 (1) , e0406
Medical Management Versus PCI in Patients with Stable Angina: An Updated Systematic Review and Meta-analysis
Background: Despite the clinical guidelines favoring medical therapy for stable angina, the optimal management of these patients remains unclear. Here, we compare medical management (MM) versus percutaneous coronary intervention (PCI) in patients with stable angina. Methods: An extensive literature search was conducted using PubMed and Embase to identify randomized controlled trials of interest. Data were extracted and analyzed using a random-effects model to calculate pooled odds ratios (OR). Results: Our meta-analysis of 28 randomized controlled trials included 9346 PCI patients and 9503 medically managed patients. The mean age was 62.5 ± 7.6 years in the PCI group and 62.8 ± 7.4 years in the other group. Men comprised 68% and 70% of the PCI and MM groups, respectively. Over a mean follow-up of 2.64 years, PCI was associated with a significantly lower incidence of myocardial infarction compared with MM (OR, 0.84; 95% CI, 0.74–0.96; P = 0.01). Although PCI showed trends toward lower odds of unplanned revascularizations and major adverse cardiovascular (CV) events, these differences were not statistically significant. There were no differences in outcomes of freedom from angina, unstable angina, nonfatal myocardial infarction, stroke, all-cause mortality, or CV death. Conclusion: Advances in CV imaging and catheterization techniques have improved risk stratification and outcomes of PCI in stable angina. Further research is needed to identify clinical subgroups that benefit most from each treatment modality.
- 18 July 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 229, 22-27
Meta-Analysis Comparing Drug-Coated Balloon Versus Plain Old Balloon Angioplasty for In-Stent Restenosis of Coronary Arteries
- 18 July 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 229, 22-27
Meta-Analysis Comparing Drug-Coated Balloon Versus Plain Old Balloon Angioplasty for In-Stent Restenosis of Coronary Arteries
- Open Access
- 15 August 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (11) , 3602-3608
Procedural safety of transcatheter aortic valve replacement with Portico valve: a systematic review
Background: The Portico transcatheter aortic heart valve is a self-expandable, fully resheathable bioprosthetic valve with a nitinol frame and porcine pericardial sealing cuff. It has been used among symptomatic severe aortic stenosis (AS) who are at high or extreme surgical risk. However, till date very few studies has been reported with inconclusive evidence for its postprocedure safety outcomes. Objective: The authors aim to evaluate the safety of the Portico transcatheter aortic valve replacement system among patients with AS. Methodology: The authors conducted a systematic literature search on PubMed, Embase, and Scopus from inception till 10th April 2023 by using predefined MESH terms using ‘AND’ and ‘OR’. The following search terms were used: ‘Aortic Stenosis’ AND ‘Transcatheter aortic valve replacement’ OR ‘Portico valve’. Finally, descriptive statistics were used to summarize the data in this paper. The mean and SD were adopted to describe continuous variables, whereas frequencies and percentages were used for dichotomous data. Results: A total of 7 studies with 2782 patients were included in the analysis. The mean age of patients was 82.3 years, and 54.63% were female. The most common comorbidity was hypertension (65.21%) and diabetes mellitus (26.45%). Among patients of AS with Portico valve implants, postprocedural outcomes including 30-day mortality (2.32%), cardiovascular mortality (2.37%), stroke (2.23%), myocardial infarction (0.94%), major bleeding (3.97%), major vascular complications (4.91%), acute kidney injury (1.37%), and permanent pacemaker implantations in 15.73% patients were reported. Overall, device success was observed in 95.82% of patients. Conclusion: Transcatheter aortic valve replacement with the repositionable Portico valve, a new bioprosthesis, appears to have a low postprocedural mortality rate and other clinical outcomes in high-risk patients with severe AS.
- 15 August 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (11) , 3602-3608
Open AccessProcedural safety of transcatheter aortic valve replacement with Portico valve: a systematic review
Background: The Portico transcatheter aortic heart valve is a self-expandable, fully resheathable bioprosthetic valve with a nitinol frame and porcine pericardial sealing cuff. It has been used among symptomatic severe aortic stenosis (AS) who are at high or extreme surgical risk. However, till date very few studies has been reported with inconclusive evidence for its postprocedure safety outcomes. Objective: The authors aim to evaluate the safety of the Portico transcatheter aortic valve replacement system among patients with AS. Methodology: The authors conducted a systematic literature search on PubMed, Embase, and Scopus from inception till 10th April 2023 by using predefined MESH terms using ‘AND’ and ‘OR’. The following search terms were used: ‘Aortic Stenosis’ AND ‘Transcatheter aortic valve replacement’ OR ‘Portico valve’. Finally, descriptive statistics were used to summarize the data in this paper. The mean and SD were adopted to describe continuous variables, whereas frequencies and percentages were used for dichotomous data. Results: A total of 7 studies with 2782 patients were included in the analysis. The mean age of patients was 82.3 years, and 54.63% were female. The most common comorbidity was hypertension (65.21%) and diabetes mellitus (26.45%). Among patients of AS with Portico valve implants, postprocedural outcomes including 30-day mortality (2.32%), cardiovascular mortality (2.37%), stroke (2.23%), myocardial infarction (0.94%), major bleeding (3.97%), major vascular complications (4.91%), acute kidney injury (1.37%), and permanent pacemaker implantations in 15.73% patients were reported. Overall, device success was observed in 95.82% of patients. Conclusion: Transcatheter aortic valve replacement with the repositionable Portico valve, a new bioprosthesis, appears to have a low postprocedural mortality rate and other clinical outcomes in high-risk patients with severe AS.
- Open Access
- 17 April 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (6) , 2849-2857
Percutaneous coronary intervention versus coronary artery bypass grafting among patients with left ventricular systolic dysfunction: a systematic review and meta-analysis
Background: Current guidelines have shown the superiority of coronary artery bypass grafting (CABG) over medical therapy. However, there is a paucity of data evaluating the optimal revascularization strategy in patients with ischemic left ventricular systolic dysfunction (LVSD). Objective: The authors aimed to evaluate the clinical outcomes of postpercutaneous coronary intervention (PCI) and CABG among patients with LVSD. Methods: The authors performed a systematic literature search using the PubMed, Embase, Scopus, and the Cochrane Libraries for relevant articles from inception until 30 November 2022. Outcomes were reported as pooled odds ratio (OR), and their corresponding 95% CI using STATA (version 17.0, StataCorp). Results: A total of 10 studies with 13 324 patients were included in the analysis. The mean age of patients in PCI was 65.3 years, and 64.1 years in the CABG group. The most common comorbidities included: HTN (80 vs. 78%) and DM (49.2 vs. 49%). The mean follow-up duration was 3.75 years. Compared with CABG, the PCI group had higher odds of all-cause mortality (OR 1.15, 95% CI 1.01–1.31, P=0.03), repeat revascularization (OR 3.57, 95% CI 2.56–4.97, PP=0.048) while the incidence of cardiovascular mortality (OR 1.23, 95% CI 0.98–1.55, P=0.07), stroke (OR 0.73 95% CI: 0.51–1.04, P=0.08), major adverse cardiovascular and cerebrovascular events (OR 1.36, 95% CI 0.99–1.87, P=0.06), and ventricular tachycardia (OR 0.79, 95% CI 0.22–2.86, P=0.72) was comparable between both the procedures. Conclusion: The results of this meta-analysis suggest that CABG is superior to PCI for patients with LVSD. CABG was associated with a lower risk of all-cause mortality, repeat revascularization, and incidence of myocardial infarction compared with PCI in patients with LVSD.
- 17 April 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (6) , 2849-2857
Open AccessPercutaneous coronary intervention versus coronary artery bypass grafting among patients with left ventricular systolic dysfunction: a systematic review and meta-analysis
Background: Current guidelines have shown the superiority of coronary artery bypass grafting (CABG) over medical therapy. However, there is a paucity of data evaluating the optimal revascularization strategy in patients with ischemic left ventricular systolic dysfunction (LVSD). Objective: The authors aimed to evaluate the clinical outcomes of postpercutaneous coronary intervention (PCI) and CABG among patients with LVSD. Methods: The authors performed a systematic literature search using the PubMed, Embase, Scopus, and the Cochrane Libraries for relevant articles from inception until 30 November 2022. Outcomes were reported as pooled odds ratio (OR), and their corresponding 95% CI using STATA (version 17.0, StataCorp). Results: A total of 10 studies with 13 324 patients were included in the analysis. The mean age of patients in PCI was 65.3 years, and 64.1 years in the CABG group. The most common comorbidities included: HTN (80 vs. 78%) and DM (49.2 vs. 49%). The mean follow-up duration was 3.75 years. Compared with CABG, the PCI group had higher odds of all-cause mortality (OR 1.15, 95% CI 1.01–1.31, P=0.03), repeat revascularization (OR 3.57, 95% CI 2.56–4.97, PP=0.048) while the incidence of cardiovascular mortality (OR 1.23, 95% CI 0.98–1.55, P=0.07), stroke (OR 0.73 95% CI: 0.51–1.04, P=0.08), major adverse cardiovascular and cerebrovascular events (OR 1.36, 95% CI 0.99–1.87, P=0.06), and ventricular tachycardia (OR 0.79, 95% CI 0.22–2.86, P=0.72) was comparable between both the procedures. Conclusion: The results of this meta-analysis suggest that CABG is superior to PCI for patients with LVSD. CABG was associated with a lower risk of all-cause mortality, repeat revascularization, and incidence of myocardial infarction compared with PCI in patients with LVSD.